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The rate at which X-ray structures of membrane proteins are solved is on a par with that of soluble
proteins in the late 1970s. There are still many obstacles facing the membrane protein structural
community. Recently, there have been several technical achievements in the ﬁeld that have started
to dramatically accelerate structural studies. Here, we summarize these so-called ‘tricks-of-the-
trade’ and include case studies of several mammalian transporters.
 2010 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction then, through the tremendous painstaking effort of many researchUntil the ﬁrst membrane protein crystal structure was solved in
1985 [1], structural analysis of membrane proteins by X-ray crys-
tallography was thought to be an unrealizable challenge. Sinceon behalf of the Federation of Euro
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versity of Oxford, South Parksgroups more than 200 unique membrane protein structures have
been solved. As more than 40% of small molecule drug targets
are aimed at membrane proteins, each high-resolution structure
is eagerly anticipated by both academia and the pharmaceutical
industry [2]. The challenges, however, still remain the same.
Chieﬂy, how to produce enough functional material and how to
coax the formation of crystals in the presence of detergent that
inherently restricts protein contacts? Here we will discuss some
technical advances in the ﬁeld. They are based on the premise that
obtaining structures of membrane proteins is hard to rationalize
from conception. These advances do not make the challenges go
away, but instead, aim to make the process quicker by recognizing
which parameters are the most important to optimize.
2. Fluorescence-based membrane protein overexpression and
monodispersity screening
What is the best parameter to screen for ﬁrst? If we work back-
wards and analyze samples of membrane proteins that form crys-
tals, we ﬁnd that in the majority of cases the membrane proteins
that form crystals tend to migrate as a single uniform peak on apean Biochemical Societies.
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the peak after size-exclusion chromatography (SEC) is an indica-
tion of the ‘‘monodispersity” of the protein solution, or more pre-
cisely the protein detergent complex. In fact, the choice of
detergent that is used to keep the protein in solution is one of
the most important parameters in dealing with membrane pro-
teins. How do we choose this detergent? A good starting point is
to ﬁrst purify the membrane protein in a detergent, such as n-
dodecyl-b-D-maltopyranoside (DDM) that has a long alkyl chain,
and consequently is relatively mild, but as we will later discuss
is not always the best for crystallization. The sample is then in-
jected onto a size-exclusion column equilibrated in several differ-
ent detergents usually of a smaller micelle-size to ﬁnd other
suitable matches. That seems reasonable if you can purify milli-
gram amounts of functional material, but what if you do not know
whether you are able to overexpress, let alone purify the mem-
brane protein in the ﬁrst place?
Our method of choice is to couple the overexpression of all our
membrane proteins with a C-terminal Green Fluorescent Protein
(GFP) tag. Although this idea was originally conceived as a folding
indicator for soluble proteins [3], it was important to verify the use
for membrane proteins as they undergo a very different folding
pathway [4]. Arguably it is a more reliable folding indicator for
membrane proteins than for globular proteins, as GFP can impose
physical restraints on the folding of soluble fusion partners in Esch-
erichia coli [5]. In contrast, membrane proteins fold co-translation-
ally, which means that GFP can only fold and become ﬂuorescent
once the upstream membrane protein has ﬁrst integrated into
the lipid bilayer [6]. If translation of the membrane protein is
uncoupled from the translocon, then synthesis follows into the
cytoplasm wherein the membrane protein aggregates to form
inclusion bodies. In this scenario the GFP tag does not have the
possibility to fold to become ﬂuorescent. The amount of mem-
brane-integrated expression can be calculated by monitoring GFP
ﬂuorescence in whole cells spectrophotometrically. Because GFP
remains folded in SDS, the integrity of the fusion can also be de-
tected after SDS–PAGE by in-gel ﬂuorescence [7]. The ﬂuorescence
is quantiﬁable, speciﬁc, and sensitive down to 5 ng and is faster
and more efﬁcient than either Western blotting or Coomassie
staining [7]. We use GFP-based pipelines in E. coli and Saccharomy-
ces cerevisiae as general workhorses for pro- and eukaryotic mem-
brane protein overexpression and puriﬁcation [7–10]. However,
the same approaches can be applied to transient expression in
mammalian and insect cells [11]. There are already many excellent
reviews on the pros and cons of each expression host and how to
optimize membrane protein overexpression and for this reason
they are not expanded on here, e.g. [12–14].
The best utility of the GFP-tag is, however, not in overexpres-
sion screening but rather in being able to monitor the monodisper-
sity of the sample in detergent-solubilized whole-cells or
membranes prior to puriﬁcation by Fluorescence-detection size-
exclusion chromatography (FSEC) [11]. This simple ‘trick’ was
developed in the lab of Eric Gouaux as a pre-crystallization screen-
ing tool on the basis that ﬂuorescence detection in crude samples
saves considerable time, resources and requires little material. In
our laboratory we generally exploit the natural variation of speciﬁc
proteins among different organisms to ﬁnd those that are most
suitable for crystallization; the GFP method is ideal in this regard
[10]. Once a suitable candidate is selected, mutants with improved
monodispersity can be screened for as elegantly highlighted by the
use of this strategy to obtain the structure of the rat ionotropic glu-
tamate AMPA receptor [15]. The reason FSEC is so useful, especially
in the absence of a suitable functional assay, is that we can already
monitor at the ﬁrst-step what we are ﬁnally aiming for. It allows
some initial judge of the quality of membrane protein produced,
since the amount of membrane-integrated expression bears noresemblance to whether the membrane protein has actually ob-
tained the correct fold for function [16]. Indeed, we monitored
the overexpression and monodispersity of 50 different eukaryotic
transporters by GFP-based ﬂuorescence using the methodology
just described and tailored for the yeast expression host S. cerevisi-
ae [17]. After comparing FSEC traces to the level of whole-cell ﬂuo-
rescence we found little correlation [10]. Of the eukaryotic
transporters that we could produce to 1 mg per liter or more in
S. cerevisiae only 60% were monodisperse in DDM [10]. A good
illustration of the potential of FSEC in selecting homologues this
way is that out of the number of transporter families we have tar-
geted to date we ﬁnd that 80% of those monodisperse in DDM can
be later puriﬁed in this detergent and 40% of this number crystal-
lize (unpublished data). To exploit FSEC fully we compare the
broadness of our FSEC traces to set membrane protein standard
peaks known to crystallize in the detergent we are screening.
One potential drawback of using GFP, as with any tag, is that
it could hinder protein function. Indeed, there are a number of
reported examples where a GFP fusion was shown to affect
function, see e.g. [18]. However, in the majority of cases GFP
is a remarkably benign protein fusion. Imaging the ﬂuorescence
acquired from C-terminal GFP-fusions it was possible to desig-
nate the organelle localization for 75% of the S. cerevisiae prote-
ome, with only a small number of mistargeted proteins;
predominantly those that harbor an C-terminal localization sig-
nal [19]. The wide use of GFP in localization studies is impor-
tant, because for many membrane proteins there exists some
prior knowledge as to whether a GFP fusion affects function. If
a C-terminal GFP fusion does inhibit function, there is the op-
tion to construct an N-terminal GFP fusion instead [20]. How-
ever, because an N-terminal GFP fusion is more likely to
disrupt membrane protein targeting and as GFP can now be
translated at a higher rate than the down-stream membrane
protein – resulting in non-tagged GFP expression – we prefer
to make a C-terminal GFP fusion ﬁrst. One limitation for expres-
sion in E. coli is that the C-terminal (or N-terminal) tail of the
membrane protein is cytoplasmic, as GFP does not fold efﬁ-
ciently across the bacterial inner membrane via the Sec translo-
case [21]. However, 80% of membrane proteins do have a Cin
topology [22], and for Cout topologies, one further option is to
consider the addition of an extra helix, e.g. from glycophorin
A (GpA). This approach was ﬁrst successfully applied to the
functional expression of the human sodium glucose cotransport-
er and more recently to a modest number of different transport-
ers [23,24]. In addition to GFP there are many other tag-probe
ﬂuorescent labeling methods, because of the limitation of pro-
tein fusions it is likely a matter of time before a ﬂuorescent
probe supersedes the ﬁrst-choice use of GFP [25].3. Detergent selection and stability consideration for obtaining
material for diffraction-grade membrane protein crystals
Even if functional milligram amounts of homogenous sample
are obtainable, there is another enormous challenge before obtain-
ing a crystal structure of a membrane protein. The detergent that is
necessary to keep the protein stable in solution can often prevent
essential crystal contacts [26]. For this reason, anecdotally it is
more difﬁcult to optimize growth of high order X-ray diffracting
crystals in mild detergents, which have longer acyl chains and
encompass more of the protein. If we compare the most successful
crystallization detergents [17], we ﬁnd that structures solved in
DDM are, on average, of lower resolution compared to those deter-
gents that have been the next most successful (Fig. 1a). Most trans-
porters have been crystallized in DDM [17], and indeed, the
median resolution for this family is the poorest at 3.3 Å
Y. Sonoda et al. / FEBS Letters 584 (2010) 2539–2547 2541(Fig. 1b). In addition to the fact that many transporters are quite
dynamic, which likely precludes their crystallization in a short-
chain detergent, a large fraction of deposited structures are of
the secondary-active type. These transporters typically lack large
hydrophilic domains and perhaps, not surprisingly, we ﬁnd that
no native X-ray structure of a secondary-active transporter has
been solved to <2.9–3.0 Å in DDM, but has in either of the short-
chain detergents DM (sodium galactose transporter vSGLT, 2.70 Å
[27]), NM (benzyl-hydantoin transporter MhpI, 2.85 Å [28]), OG
(leucine transporter LeuT, 1.6 Å [29]), or OTG (Na+-independent
amino acid transporter ApcT, 2.35 Å) [30]. Clearly, for proteins such
as the secondary-active transporters that do not crystallize in a
small chain detergent a 3–4 Å-resolution structure is better than
no structure at all. However, there is the caveat that as more struc-
tures of similar proteins are becoming available (e.g. the recent
structures with the LeuT-fold [29]) the goal is not to see the overall
architecture of the protein but rather to be able to decipher the
structural details and this requires higher resolution.
There are two complementary strategies used by our laboratory
and others to work around this inherent problem. The ﬁrst ap-
proach is to co-crystallize with a monoclonal antibody or some
protein fusion, as an extra soluble domain will increase the acces-
sible surface area for crystal contacts. The excellent utility ofR
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Fig. 1. Exploring the correlation between structural resolution and the type of
crystallization detergent. A database was built by collecting the crystallization
information from all of the currently available unique alpha-helical MP structures
in the PDB. Only structures crystallized using a single deﬁned detergent were
included. This task was greatly facilitated by the ‘Membrane Proteins of Known 3D
Structure’ web site from the Stephen White laboratory at UC Irvine (http://
blanco.biomol.uci.edu/Membrane_Proteins_xtal.html) (a). Box plots displaying the
structural resolution for seven of the most successful crystallization detergents
[17]; the middle line in each plot represents the median. (b) Deposited structural
resolution for the different membrane protein family members.monoclonal Ab co-crystallization was ﬁrst proven possible by the
crystal structure of cytochrome c oxidase complexed with an Fv
fragment [31] and since then several membrane protein co-crystal
structures predominantly with Fab fragments, e.g. [32,33]. The
E. coli H+/Cl exchanger highlights a nice example of the higher res-
olution that can be afforded by this approach; Fab fragment co-
crystallized improves structural resolution from 3.5 to 2.5 Å
[34,35]. As you might expect good X-ray diffraction may not be
obtainable without the Fab fragment. Moreover as more groups
aim towards mammalian membrane protein structures, due to an
apparent lack of stability in short-chain detergents, it is likely
Fab fragment co-crystallization will become increasingly popular.
In addition to improving crystallization, Fab fragments have an
advantage in that they can be used for phasing. The advantage of
phasing this way cannot be underestimated; phasing membrane
protein structural data is generally difﬁcult. We anticipate that
the use of Fab fragment co-crystallization is likely to be dependent
on whether the mammalian membrane proteins used for structural
studies do, or do not, contain large hydrophilic domains. For pro-
tein fusions, the use of designed ankyrin-repeat proteins (DARPins)
in principle offer all the same beneﬁts as Fab fragments [36]. These
are made up of variable number of ankyrin units, a naturally occur-
ring 33 residue motif present in many proteins, and speciﬁc bind-
ers can be screened for using repeat protein libraries by standard
screening technologies such as ribosome display. The multidrug ef-
ﬂux-pump AcrB co-crystal DARPin structure was solved to signiﬁ-
cantly higher resolution at 2.54 Å, and testiﬁes to the potential of
this approach [37]. More speciﬁc protein fusion strategies has been
the remarkable successfulness of the soluble T4–lysozyme fusion
to the third intracellular loop of several GPCRs in combination with
lipidic-cubic phase crystallization [38] as has recently been well
documented, see e.g. [39]. Time will tell whether these insightful
approaches can be successfully applied to a greater number of dif-
ferent membrane proteins.
Simplistically, the scaffold approach aims to increase crystal
contacts in a mild detergent. The alternative strategy is to try
and stabilize the membrane protein by mutagenesis so that it
now becomes possible to crystallize in a small micelle detergent
instead and so exposing a larger surface area of the protein.
Encouragingly, as illustrated by Bowie and co-workers membrane
proteins, in contrast to soluble proteins, are particularly suscepti-
ble to stabilization by mutagenesis, perhaps because there has
been less evolutionary pressure applied by the lipid bilayer in com-
parison to the hydrophobic effect [40,41]. This was the contrasting
approach used by Tate and colleagues to obtain the turkey b1-
adrenergic GPCR structure [42]. The conformational thermostabi-
lized receptor was generated by initially screening systematic ala-
nine mutants that bound more of the antagonist dihydroalprenolol
than the wild-type receptor after heating [43]. The heterologous
expression of the receptor in E. coli meant measurements could
be made directly from isolated membranes solubilized in DDM.
Minor truncations together with six different mutations were ﬁnal-
ly combined to maximize the stability of the receptor in the antag-
onist bound-state that when puriﬁed from insect cells formed
well-ordered crystals in the short-chain detergent OTG [42]. This
study is an important conceptual milestone. It adds support to
the idea that detergent stability and conformational ﬂexibility
are the intrinsically linked factors affecting the growth of well-or-
dered membrane protein crystals in small micelle-sized
detergents.
To monitor the stability of a membrane protein requires some
method. In the above case there is a good ligand-binding assay avail-
able so that activity could be measured in a relatively straightfor-
ward manner, but this is not always the case. In addition
to standard biophysical methods such as Circular dichroism
spectroscopy [41], one new approach has been to monitor cysteine
Fig. 2. Using the CPM assay to screen for mercury derivatization. The CPM assay
was carried out essentially as described by Stevens and co-workers [44,70]. One
microliter of puriﬁed bacterial transporter pre-incubated with and without 2.5 mM
mercury acetate and subjected to SEC at 10 mg/ml was added to 150 ll of buffer
containing 20 mM Tris–HCl, pH 7.5, 0.1 M NaCl, and detergent at 0.03% DDM in a
96-well black Nunc plate. Three microliters of CPM dye (diluted from a 4 mg/ml
stock in dimethyl sulfoxide) at 40 lg/ml was added, clear plate cover set in place,
and within 5 min from protein addition ﬂuorescence emission was measured at
463 nm (excitation 387 nm) on the SpectraMax2e plate reader (Molecular Devices)
at 40C. Recordings were measured every 5 min for 130 min with 15 sec shaking
between each interval readings; ﬁlled diamond, ion transporter with no Hg2+
addition; ﬁlled circles, Cys-less ion transporter; open squares, ion transporter pre-
incubated with Hg2+ addition; ﬁlled triangles, no protein addition.
Optimization of pre-crystallization condition 
 • Stability-based screening  (CPM assay)
 • Removing of disordered region if necessary
 • Detergent exchange into short-chain 
                detergent if possible
 • Raising mAb
Crystallization
 • General crystallization screening
 • Additive screening
Phasing
 • Se-Met derivative
 • Heavy metal derivative
 (CPM assay can be applicable for Hg2+)
Membrane protein-GFP fusion overexpression screening 
 • Whole cell fluorescence
 • Localization
 • In-gel fluorescence
Screening of transporter homologues
for monodispersity in DDM by FSEC
Purification in DDM
 • IMAC
 • GFP-His8 removal and dialysis
 • Reverse Ni-NTA
 • SEC
Fig. 3. Schematic ﬂow diagram illustrating the steps towards crystal structures of
transporters.
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maleimideprobe N-[4-(7-diethylamino-4-methyl-3-coumarinyl)-
phenyl]maleimide (CPM) that becomes ﬂuorescent when it forms
a disulﬁde bond [44]. This assay relies on the premise thatmost cys-
teines are buried in transmembranes (TMs) meaning that their
accessibility to the dye can be used to evaluate membrane protein
stability [44]. Stevens and co-workers developed the proof-of-
concept for this assay using three different proteins, and was later
applied to the human b2-adrenergic receptor T4–lysozyme fusion
to show that the addition of cholesterol hemisuccinate (CHS) and
the partial inverse agonist timolol signiﬁcantly improves stability
[45].
Maleimide ﬂuorescent-conjugated dyes can also be used to help
in phasing. When the structure cannot be solved by molecular
replacement derivatizing the protein with mercury (Hg2+), which
commonly binds to free sulfhydryl groups of cysteine residues, is
often one of the most efﬁcient ways to obtain initial phases, see
e.g. [46]. If Hg2+ is ﬁrst incubated with the protein and it binds to
the –SH groups of cysteine residues then the thiol-based dye is pre-
vented from conjugating [47]. By comparing the loss of in-gel ﬂuo-
rescent band intensity in SDS–PAGE gels with protein that has
been incubated with and without Hg2+ prior to addition of the
dye, it is possible to screen for the optimal Hg2+ compound to
use and its minimum concentration required for complete deriva-
tization [47]. By using the CPM dye we also ﬁnd that we can em-
ploy a similar strategy to conﬁrm Hg2+ derivatization (Fig. 2).
4. Case studies for the optimization of mammalian transporters
for structural studies
In Fig. 3, we have outlined a general approach towards obtain-
ing structures of transporters. It should be stressed that although
we strive to obtain stable proteins in short-chain detergents this
does not mean that we exclude other avenues. More often than
not the ﬁrst crystallization trials performed are carried out with
the protein concentrated in DDM. As might be expected we also
try to improve any crystals using standard crystallization tech-
niques. In this regard an effective trick is to try different detergents
as additives during the crystallization and to screen any crystals
obtained for diffraction at the synchrotron. In parallel we continueto ﬁnd other constructs that can be exchanged into short-chain
detergents and also consider the antibody approach as this often
leads to higher resolution data more quickly than the optimization
of a membrane protein crystallized in DDM.
Taken together, although the crystallization screens used by
membrane protein structural biologists differ, the general consen-
sus is that success is predominantly based upon having membrane
proteins that are monodisperse, functional and stable. Here, we
demonstrate the practical application of these methods for isola-
tion of the rat vesicular glutamate transporter VGLUT2 and the hu-
man glucose transporter GLUT1.
4.1. Case study 1: vesicular glutamate transporter, VGLUT2
Glutamate is a major excitatory neurotransmitter that plays an
essential role for higher neural function such as plasticity, memory,
and learning in the central nervous system. Glutamate is stored in
synaptic vesicles prior to its depolarization-triggered, calcium-
dependent release from neuron terminals [48,49]. VGLUTs are
Y. Sonoda et al. / FEBS Letters 584 (2010) 2539–2547 2543responsible for the vesicular storage of glutamate and play an
essential role in glutamatergic signal transmission in the central
nervous system. So far, three isoforms of VGLUT have been identi-
ﬁed, VGLUT1, VGLUT2 and VGLUT3 [50]. The helices are highly
homologous, 90% identical in their amino acid sequence, while
their N- and C-terminal tails have little homology. VGLUT-medi-
ated L-glutamate transport into synaptic vesicles is dependent on
a membrane potential set by the vesicular H+-ATPase [51]. VGLUT2
is trafﬁcked into vesicular membrane of synaptic cells [48,49], and
in COS7 cells distributes into endosomes [52].
Using our standard protocol (see Ref. [9] for step-by-step de-
tails) rat VGLUT2–GFP–His8 overexpresses to nearly 1 mg per liter
of S. cerevisiae culture as calculated by whole-cell ﬂuorescence [9].
VGLUT2 localizes to the vacuolar membrane in S. cerevisiae consis-
tent with the results obtained from mammalian cultures (Fig. 4).
Using crude-membranes of VGLUT2 expressing cells for SDS–PAGE,
a band at the correct molecular weight was apparent at 80–90 kDa
as detected by in-gel ﬂuorescence (Fig. 4b) [7]. 65% of VGLUT2–
GFP–His8 fusion is extracted by Foscholine-12, compared to 58%
and 46% for the maltoside detergents DDM and DM, respectively.
However, it is clear by FSEC analysis that the major amount ofa
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Fig. 4. Overexpression and monodispersity screening of rat VGLUT2–GFP–His8 fusion
cerevisiae cells. Left and right panel indicate ﬂuorescence and differential interference co
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gates (Fig. 4c). VGLUT2–GFP–His8 is poorly monodisperse in DDM
and DM and migrates as a broad proﬁle with a large ‘free’ GFP peak
presumably as a result of degraded VGLUT2 (Fig. 4c). Cholesterol is
a stabilizer for several mammalian membrane proteins [53]. As S.
cerevisiae membranes do not contain cholesterol [54], 0.2% CHS
was added to each detergent solubilization test. The addition of
CHS improved detergent extraction efﬁciency and monodispersity
of VGLUT2–GFP–His8 fusion most noticeably in DM-solubilized
membranes. Based on FSEC proﬁles, DM with the addition of CHS
was selected as detergents for puriﬁcation (Fig. 4c).
After identifying suitable puriﬁcation conditions we could re-
clone the gene for rat VGLUT2 and purify with a standard hexa-
histidine tag only [55]. However, our experience is that it is informa-
tive to visually monitor puriﬁcation by ﬂuorescence as it enables
each step to be recorded easily, e.g. cell-breakage efﬁciency, deter-
gent solubilization efﬁciency, nickel-nitrilotriacetic acid (Ni-NTA)
binding efﬁciency. The C-terminal GFP-fusion encodes an octahisti-
dine-tag with a tobacco etch virus protease (TEV) protease cleavage
site for GFP–His8 removal [6]. After immobilizedmetal afﬁnity chro-
matography (IMAC), VGLUT2–GFP–His8 remained monodisperse,b 1
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in S. cerevisiae. (a) Typical confocal image of VGLUT2–GFP–His8 localization in S.
ntrast images, respectively. (b) In-gel ﬂuorescence detection of VGLUT2–GFP–His8
ring empty vector; 3, membranes from cells overexpressing VGLUT2–GFP–His8;
ackground protein, respectively. (c) FSEC proﬁles of VGLUT2–GFP–His8 in detergent-
ergent-solubilized membranes were injected onto a Superose 6 10/300 column (GE-
ured at 512 nm by excitation at 470 nm; asterisk indicates endogenous ﬂuorescent
2544 Y. Sonoda et al. / FEBS Letters 584 (2010) 2539–2547however, there was a large ‘free’ GFP peak that suggests further
VGLUT2 degradation during puriﬁcation (Fig. 5a). Although the S.
cerevisiae strain used for membrane protein overexpression has
the pep4 gene coding for the vacuolar protease deleted and protease
inhibitors areusedduringpuriﬁcation, proteolysis forVGLUT2 is still
a problem. For this reasonwe engineered anN-terminal FLAG tag on
the basis of a study that showed degradation of the H+-ATPase
Pma1p in S. cerevisiae could be minimized by addition of a soluble
N-terminal fusion [56].
The recovery of VGLUT2–GFP–His8 after puriﬁcation was im-
proved in the presence of the FLAG tag, and was used in an addi-
tional tag for puriﬁcation (Fig. 5a). After IMAC and FLAG tag
puriﬁcation, 1 mg of pure VGLUT2–GFP–His8 was isolated from
10 l of yeast culture (Fig. 5b). The transport of L-glutamate by
VGLUT2 requires a membrane potential [48]. We incorporated
the VGLUT2–GFP–His8 fusion, VGLUT2 after GFP–His8 removal,
and VGLUT2–His6 puriﬁed from insect cells together with bacterial
F0F1-ATPase into proteoliposomes and measured ATP dependent L-
glutamate uptake (Fig. 5c) [55]. Puriﬁed VGLUT2–GFP–His8 anda
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into proteoliposomes with the bacterial F0F1-ATPase. The ATP-dependent transport activVGLUT2 from S. cerevisiae cells possesses almost identical func-
tional activity to that of VGLUT2 puriﬁed from insect cells.
4.2. Case study 2: facilitative glucose transporter, GLUT1
Glucose is an essential energy source for mammalian cells.
Mammalian glucose transporters are classiﬁed into two distinct
groups, sodium glucose cotransporters (SGLT) and facilitative glu-
cose transporters (GLUT). SGLT1 and SGLT2 transport glucose by a
secondary-active transport mechanism [57], while several GLUTs
mediate passive transport of glucose [58]. Among 14 GLUT mem-
bers, GLUT1 is well characterized and is widely distributed into
many tissues, especially abundant in human erythrocytes. Since
the ﬁrst identiﬁcation of GLUT1 puriﬁed from Triton X-100-solubi-
lized membranes [59], many research groups have isolated human
GLUT1 from erythrocyte membranes by ion exchange chromatog-
raphy [60–64]. However, it seems probable that heterogeneous
glycosylation [65] has been an obstacle to crystallize GLUT1 puri-
ﬁed from this native source [64].b
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[71], and the lipid was sonicated to make unilamellar liposomes. 500 lL of a mixture containing 10 lg of puriﬁed GLUT1 and 20 mg of liposomes in 10 mM TrisSO4 (pH 7.5)
was ﬂash frozen and thawed at room temperature. Large, unilamellar proteoliposomes were prepared by extrusion 11 times (LiposoFast, Avestin; membrane pore size,
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described [69]. (a) Time course of D-glucose transport in proteoliposomes (0.1 lg GLUT1, 0.6 mg lipid) was measured (solid line). Non-speciﬁc uptake was estimated with
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Y. Sonoda et al. / FEBS Letters 584 (2010) 2539–2547 2545Recently, it was reported that GLUT1 could be successfully over-
produced and puriﬁed from Pichia pastoris [66] and Schizosaccharo-myces pombe [67]. We have also been working with GLUT proteins,
and the GLUT1–GFP–His8 construct overexpresses in S. cerevisiae at
2546 Y. Sonoda et al. / FEBS Letters 584 (2010) 2539–25472 mg per liter of culture (Fig. 6a). Monitoring by FSEC it is clear
that GLUT1–GFP–His8 migrates as a symmetrical monodisperse
peak in DDM-solubilized membranes (Fig. 6b). Our standard puri-
ﬁcation protocol after IMAC is to cleave the puriﬁed GFP–His8 fu-
sion with equimolar His6-TEV protease during dialysis overnight
at 10 C. The reason for this is twofold, ﬁrst dialysis dilutes out
imidazole and secondly we equilibrate into the buffer used for
crystallization. Dialysis into the crystallization buffer adds the ex-
tra option to use this material directly for crystallization, as there
remains the possibility that omitting SEC produces better crystals
[68]. Passing the digested material through a 5-ml HisTrap™ col-
umn in the absence of imidazole, the cleaved GFP–His8 fusion,
His6-TEV protease and remaining inadvertent contaminants bind
to the resin. By collecting the ﬂow-through from the HisTrap™ col-
umn pure GLUT1 was recovered (Fig. 6c). The ﬁnal yield of GLUT1
is 2 mg from 10 l of yeast culture.
GLUT1 was reconstituted into liposomes by a freeze–thaw/
extrusion method. D-Glucose transport and non-speciﬁc L-glucose
uptake into GLUT1 proteoliposomes was measured as described
previously (Fig. 7a) [69]. As expected, the known inhibitors cyto-
chalasin B and phloretin signiﬁcantly inhibited D-glucose transport
(Fig. 7b). Interestingly, after mixing puriﬁed GLUT1 with lipids,
successful reconstitution was found to be best by including a
freeze/thaw treatment (Fig. 7c); as far as we are aware this is the
ﬁrst time the importance of this step has been noted. Using this
similar strategy we have been able to purify milligram amounts
of several mammalian GLUTs in an active form (unpublished data).
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